ALTEROLA BIOTECH INC.
alterola-abti.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2025 10-Q, filed Nov 29, 2024. Its latest SEC filing is a 15-15D from Jun 30, 2025.
10-Q for Q2 FY2025, filed Nov 29, 2024
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops cannabinoid and cannabinoid-like medicines for patients, along with pharmaceutical and food ingredients for human and animal health markets.
10-K for FY2024, filed Jul 18, 2024Our goal is to provide better medicines for patients around the world. We believe in harnessing the therapeutic potential of cannabinoids…View ↗
1) Development of regulated pharmaceuticals (human and animal health) and regulated food products. This has been achieved via the strategic…View ↗
2) Production of low cost of goods Active Pharmaceutical Ingredient (API) and food-grade ingredients (supported by the strategic…View ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2025, filed Nov 28, 2024
−$799.2KView ↗
- ▲ +549% (Loss)
- vs −$123.2K in Q2 FY2024
-
Jun 30, 2025
Protagenic acquired Phytanix through a share exchange
Alterola and EMC2 exchanged their Phytanix shares for Protagenic securities; Alterola said it intends to end SEC registration and become privately held.
Sources
8-K, filed Jun 30, 2025
On May 15, 2025, Protagenic Therapeutics, Inc., a Delaware corporation (the “Protagenic”), entered into the Share Exchange Agreement (the…View ↗
-
Sep 30, 2024
Company said its quarterly balance sheet needed restatement
An error in consolidating subsidiaries affected the unaudited balance sheet; the company said the change was non-cash and did not affect revenue or net income.
Sources
8-K, filed Sep 30, 2024
On September 24, 2024, the board of directors of Alterola Biotech, Inc. (the “Company”) determined, upon the recommendation of the…View ↗
Loading...
